Cargando…
Fibroblast growth factor 21 inhibition aggravates cardiac dysfunction in diabetic cardiomyopathy by improving lipid accumulation
Diabetic cardiomyopathy (DCM) is one of the major causes of morbidity and mortality in diabetic patients. Recent studies have demonstrated an increased level of fibroblast growth factor 21 (FGF21) in the plasma of DCM patients, and FGF21 has been proven to be a cardiovascular protector of the heart....
Autores principales: | Chen, Cui, Meng, Zheying, Zheng, Yuanyi, Hu, Bing, Shen, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763648/ https://www.ncbi.nlm.nih.gov/pubmed/29375676 http://dx.doi.org/10.3892/etm.2017.5375 |
Ejemplares similares
-
FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation
por: Yan, Xiaoqing, et al.
Publicado: (2015) -
Hypoglycemia-Exacerbated Mitochondrial Connexin 43 Accumulation Aggravates Cardiac Dysfunction in Diabetic Cardiomyopathy
por: Wei, Xing, et al.
Publicado: (2022) -
Protective effects of rolipram on endotoxic cardiac dysfunction via inhibition of the inflammatory response in cardiac fibroblasts
por: Ji, Jingjing, et al.
Publicado: (2020) -
Mechanism of fibroblast growth factor 21 in cardiac remodeling
por: Zhao, Zeyu, et al.
Publicado: (2023) -
Reduced fatty acid uptake aggravates cardiac contractile dysfunction in streptozotocin-induced diabetic cardiomyopathy
por: Umbarawan, Yogi, et al.
Publicado: (2020)